

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the present application.

Listing of Claims:

1. (Currently Amended) A method for increasing the systemic exposure of cells selected from tumor cells and normal cells to an orally administered pharmaceutically active compound, comprising:

orally administering wherein a bioenhancer comprising an inhibitor of BCRP is orally administered concomitantly with said orally administered and said pharmaceutically active compound, wherein said inhibitor and said pharmaceutically active compound are concomitantly exposed to said cells.

2. (Original) Method according to claim 1, wherein the inhibitor is administered simultaneously with the pharmaceutical compound.

3. (Previously Presented) Method according to claim 1, wherein the cells are normal cells.

4. (Previously Presented) Method according to claim 1, wherein the inhibitor is a selective inhibitor of BCRP.

5. (Previously Presented) Method according to claim 1, wherein the inhibitor is selected from acridine derivatives, quinoline derivatives, isoquinoline derivatives and combinations thereof.

6. (Previously Presented) Method according to claim 1, wherein the inhibitor is GF120918, XR 9051 or XR 9576.

7. (Previously Presented) Method according to claim 1, wherein the bioenhancer is a mycotoxin.

8. (Original) Method according to claim 7, wherein the mycotoxin is fumitremorgin C.

9. (Previously Presented) Method according to claim 1, wherein the bioenhancer has a higher affinity for BCRP than for P-gp.

10. (Previously Presented) Method according to claim 1, wherein the bioenhancer has a higher affinity for BCRP than for MRP.

11. (Previously Presented) Method according to claim 1, wherein the bioenhancer inhibits binding of ATP to a BCRP mediated and/or related drug transport protein.

12. (Original) Method according to claim 11, wherein the protein is BCRP.

13. (Previously Presented) Method according to claim 1, wherein the pharmaceutically active compound is selected from the group consisting of indolizino-quinoline derivatives, camptothecin derivatives, anthraquinone derivatives and quinazoline derivatives.

14. (Original) Method according to claim 13, wherein the pharmaceutically active compound is an indolizino-quinoline derivative.

15. (Original) Method according to claim 13, wherein the pharmaceutically active compound is a camptothecin derivative.

16. (Original) Method according to claim 15, wherein the pharmaceutically active compound is selected from the group consisting of topotecan, GG211, DX8951f, BNP1350, 9-aminocamptothecin, 9-nitrocamptothecin, CPT11 and any metabolites thereof.

17. (Original) Method according to claim 16, wherein the metabolite is SN38.

Application No. 09/988,285

Art Unit

Response to Office Action dated August 8, 2003

October 14, 2003

18. (Original) Method according to claim 13, wherein the pharmaceutically active compound is an anthraquinone derivative.

19. (Original) Method according to claim 18, wherein the pharmaceutically active compound is mitoxantrone.

20. (Original) Method according to claim 13, wherein the pharmaceutically active compound is a quinazoline derivative.

21. (Original) Method according to claim 20, wherein the pharmaceutically active compound is prazosin.

22. (Original) Pharmaceutical composition comprising a bioenhancer and a pharmaceutically active compound, said bioenhancer comprising an inhibitor of BCRP and said pharmaceutically active compound being selected from the group consisting of indolizino-quinoline derivatives, camptothecin derivatives, anthraquinone derivatives and quinazoline derivatives.

23-29. Canceled.

30. (New) A pharmaceutical composition, comprising:
an effective amount of topotecan; and

an effective bioenhancing amount of GF120918.

31. (New) The pharmaceutical composition of claim 30, further comprising a pharmaceutically acceptable carrier suitable for oral administration.

32. (New) A method for increasing the systemic exposure of cells selected from tumor cells and normal cells to orally administered camptothecin or a cytostatic camptothecin derivative, comprising:

orally administering an effective bioenhancing amount of GF120918 to said cells wherein said GF120918 and said camptothecin or said cytostatic camptothecin derivative are both present at overlapping periods of time.

33. (New) The method according to claim 32, wherein the GF120918 is administered simultaneously with the camptothecin or cytostatic camptothecin derivative.

34. (New) The method according to claim 32, wherein said camptothecin or cytostatic camptothecin derivative is topotecan.